1. Acknowledgement to Referees

   Acknowledgement to Referees 20 November 2014 Pages: 2105 - 2109

2. The Biology and Clinical Development of MEK Inhibitors for Cancer

   • Jason J. Luke
   • Patrick A. Ott
   • Geoffrey I. Shapiro

   Leading Article 21 November 2014 Pages: 2111 - 2128

   

3. Intensive Intervention Can Lead to a Treatment Holiday from Biological DMARDs in Patients with Rheumatoid Arthritis

   • Yoshiya Tanaka
   • Shintaro Hirata

   Leading Article Open access 12 November 2014 Pages: 2129 - 2139

4. Combining a GLP-1 Receptor Agonist and Basal Insulin: Study Evidence and Practical Considerations

   • Nicholas W. Carris
   • James R. Taylor
   • John G. Gums

   Therapy in Practice 21 November 2014 Pages: 2141 - 2152

5. Rifaximin: A Review of Its Use in Reducing Recurrence of Overt Hepatic Encephalopathy Episodes

   • Lesley J. Scott

   Adis Drug Evaluation 29 October 2014 Pages: 2153 - 2160

   

6. Liraglutide: A Review of Its Use in Adult Patients with Type 2 Diabetes Mellitus

   • Lesley J. Scott

   Adis Drug Evaluation 04 November 2014 Pages: 2161 - 2174

   

7. Pramipexole Extended-Release: A Review of Its Use in Patients with Parkinson’s Disease

   • James E. Frampton

   Adis Drug Evaluation 11 November 2014 Pages: 2175 - 2190

8. Dapagliflozin: A Review of Its Use in Patients with Type 2 Diabetes

   • Greg L. Plosker

   Adis Drug Evaluation 12 November 2014 Pages: 2191 - 2209

   

9. Ripasudil: First Global Approval

   • Karly P. Garnock-Jones

   R&D Insight Report 21 November 2014 Pages: 2211 - 2215

   

10. Erratum to: New Directions for Rabbit Antithymocyte Globulin (Thymoglobulin^®) in Solid Organ Transplants, Stem Cell Transplants and Autoimmunity

    • Mohamad Mohty
    • Andrea Bacigalupo
    • Yvon Lebranchu

    Erratum 25 November 2014 Pages: 2217 - 2217